Epidemiology, staging, and clinical characteristics

Surgery for Ovarian Cancer: Principles and Practice

Volumn , Issue , 2010, Pages 1-23

  Chu, Christina S ^a   Rubin, Stephen C ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056038182     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781841847825     Document Type: Chapter

References (235)

1. Tortolero-Luna G, Mitchell MF, Rhodes-Morris HE. Epidemiology and screening of ovarian cancer. Obstet Gynecol Clin North Am 1994; 21:1-23.
2. Baker TR, Piver MS. Etiology, biology, and epidemiology of ovarian cancer. Semin Surg Oncol 1994; 10:242-248.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
4. Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Am J Obstet Gynecol 1986; 154:639-647.
5. Ries LAG, Kosary CL, Hankey BF, et al., eds. Cancer statistics review 1973-1994. Bethesda, MD: National Cancer Institute, 1997.
6. McGowan L, Parent L, Lednar W, et al. The woman at risk for developing ovarian cancer. Gynecol Oncol 1979; 7:325-344.
7. Parazzini F, La Vecchia C, Negri E, et al. Menstrual factors and the risk of epithelial ovarian cancer. J Clin Epidemiol 1989; 42:443-448.
8. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1212-1220.
9. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771-776.
10. Casagrande JT, Louie EW, Pike MC, et al. “Incessant ovulation” and ovarian cancer. Lancet 1979; 2:170-173.
11. Keal EE. Asbestosis and abdominal neoplasms. Lancet 1960; 2:1211-1216.
12. Newhouse ML, Pearson RM, Fullerton JM, et al. A case control study of carcinoma of the ovary. Br J Prev SocMed 1977; 31:148-153.
13. Graham J, Graham R. Ovarian cancer and asbestos. Environ Res 1967; 1:115-128.
14. Henderson WJ, Hamilton TC, Griffiths K. Talc in normal and malignant ovarian tissue. Lancet 1979; 1:499.
15. Longo DL, Young RC. Cosmetic talc and ovarian cancer. Lancet 1979; 2:1011-1012.
16. Venter PF. Ovarian epithelial cancer and chemical carcinogenesis. Gynecol Oncol 1981; 12:281-285.
17. Hartge P, Hoover R, Lesher LP, et al. Talc and ovarian cancer. JAMA 1983; 250:1844.
18. Roe FJ. Controversy: cosmetic talc and ovarian cancer. Lancet 1979; 2:744.
19. Whittemore AS, Wu ML, Paffenbarger RS Jr., et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 1988; 128:1228-1240.
20. Cramer DW, Welch WR, Scully RE, et al. Ovarian cancer and talc: a case-control study. Cancer 1982; 50:372-376.
21. Cook LS, Kamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol 1997; 145:459-465.
22. Lingeman CH. Environmental factors in the etiology of carcinoma of the human ovary: a review. Am J Ind Med 1983; 4:365-379.
23. Beral V, Fraser P, Chilvers C. Does pregnancy protect against ovarian cancer? Lancet 1978; 1:1083-1087.
24. dos Santos Silva I, Swerdlow AJ. Recent trends in incidence of and mortality from breast, ovarian and endometrial cancers in England and Wales and their relation to changing fertility and oral contraceptive use. Br J Cancer 1995; 72:485-492.
25. Roush GC, Holford TR, Schymura MJ, et al. Cancer Risk and Incidence Trends: The Connecticut Perspective. New York: Hemisphere, 1987.
26. Buell P, Dunn JE. Cancer mortality among the Japanese Issei and Nisei of California. Cancer 1965; 18:656-664.
27. Parker SL, Davis KJ, Wingo PA, et al. Cancer statistics by race and ethnicity. CA Cancer J Clin 1998; 48:31-48.
28. Annegers JF, Strom H, Decker DG, et al. Ovarian cancer: incidence and case-control study. Cancer 1979; 43:723-729.
29. West RO. Epidemiologic study of malignancies of the ovaries. Cancer 1966; 19:1001-1007.
30. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol 1984; 11:209-226.
31. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer-a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993; 71:582-588.
32. Menczer J, Modan M, Ranon L, et al. Possible role of mumps virus in the etiology of ovarian cancer. Cancer 1979; 43:1375-1379.
33. Cramer DW, Welch WR, Cassells S, et al. Mumps, menarche, menopause, and ovarian cancer. Am J Obstet Gynecol 1983; 147:1-6.
34. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 1986; 58:2363-2371.
35. Cramer DW, Harlow BL, Willett WC, et al. Galactose consumption and metabolism in relation to the risk of ovarian cancer. Lancet 1989; 2:66-71.
36. Stocks P. Cancer mortality in relation to national consumption of cigarettes, solid fuel, tea and coffee. Br J Cancer 1970; 24:215-225.
37. Trichopoulos D, Papapostolou M, Polychronopoulou A. Coffee and ovarian cancer. Int J Cancer 1981; 28:691-693.
38. Byers T, Marshall J, Graham S, et al. A case-control study of dietary and nondietary factors in ovarian cancer. J Natl Cancer Inst 1983; 71:681-686.
39. Cramer DW, Welch WR, Hutchison GB, et al. Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol 1984; 63:833-838.
40. Slattery ML, Schuman KL, West DW, et al. Nutrient intake and ovarian cancer. Am J Epidemiol 1989; 130:497-502.
41. Fairfield KM, Hankinson SE, Rosner BA, et al. Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 2001; 92:2318-2326.
42. Koch M, Gaedke H, Jenkins H. Family history of ovarian cancer patients: a case-control study. Int J Epidemiol 1989; 18:782-785.
43. Hartge P, Schiffman MH, Hoover R, et al. A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161:10-16.
44. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol 1992; 80:700-707.
45. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am J Hum Genet 1989; 45:521-529.
46. Houlston RS, Collins A, Slack J, et al. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet 1991; 55(pt 4):291-299.
47. Bewtra C, Watson P, Conway T, et al. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 1992; 11:180-187.
48. Narod SA, Madlensky L, Bradley L, et al. Hereditary and familial ovarian cancer in southern Ontario. Cancer 1994; 74:2341-2346.
49. Lynch HT, Lynch JF, Conway TA. Hereditary ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian Cancer. New York: McGraw-Hill, 1993:189-217.
50. Lynch HT, Harris RE, Guirgis HA, et al. Familial association of breast/ovarian carcinoma. Cancer 1978; 41:1543-1549.
51. Berchuck A, Cirisano F, Lancaster JM, et al. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 1996; 175:738-746.
52. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
53. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378:789-792.
54. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004; 95:866-871.
55. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88:265-275.
56. Chen J, Silver DP, Walpita D, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998; 2:317-328.
57. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med 1997; 3:721-722.
58. Zhang H, Tombline G, Weber BL. BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell 1998; 92:433-436.
59. Kadouri L, Hubert A, Rotenberg Y, et al. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 2007; 44:467-471.
60. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358-1365.
61. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91:1310-1316.
62. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995; 55:2998-3002.
63. Schildkraut JM, Thompson WD. Familial ovarian cancer: a population-based case-control study. Am J Epidemiol 1988; 128:456-466.
64. Couch FJ, Hartmann LC. BRCA1 testing-advances and retreats. JAMA 1998; 279:955-957.
65. Malone KE, Daling JR, Thompson JD, et al. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with firstdegree family history. JAMA 1998; 279:922-929.
66. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993; 52:678-701.
67. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62:676-689.
68. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401-1408.
69. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335:1413-1416.
70. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283:2260-2265.
71. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260:812-816.
72. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75:1215-1225.
73. Bellacosa A, Genuardi M, Anti M, et al. Hereditary nonpolyposis colorectal cancer: review of clinical, molecular genetics, and counseling aspects. Am J Med Genet 1996; 62:353-364.
74. Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 1999; 36:801-818.
75. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430-433.
76. Burke W, Daly M, Garber J, et al. Recommendations for followup care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277:997-1003.
77. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol 1996; 14:1730-1736; discussion 7-40.
78. Mackey SE, Creasman WT. Ovarian cancer screening. J Clin Oncol 1995; 13:783-793.
79. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273:491-497.
80. van Nagell JR Jr., DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000; 77:350-356.
81. van Nagell JR Jr., Gallion HH, Pavlik EJ, et al. Ovarian cancer screening. Cancer 1995; 76:2086-2091.
82. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109:221-227.
83. van Nagell JR Jr., DePriest PD, Ueland FR, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 2007; 109:1887-1896.
84. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997; 277:915-919.
85. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339:424-428.
86. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345:235-240.
87. Ness RB, Grisso JA, Vergona R, et al. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 2001; 12:307-312.
88. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a casecontrol study. Lancet 2001; 357:1467-1470.
89. Streuwing JP, Watson P, Easton EF, et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Natl Cancer Inst Monogr 1995:33-35.
90. Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2:795-797.
91. Mangan CE, Rubin SC, Rabin DS, et al. Lymph node nomenclature in gynecologic oncology. Gynecol Oncol 1986; 23:222-226.
92. Keettel WC, Pixley EE. Diagnostic value of peritoneal washings. Clin Obstet Gynecol 1958; 1:592.
93. Feldman GB, Knapp RC, Order SE, et al. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972; 32:1663-1666.
94. Holm-Nielsen P. Pathogenesis of ascites in peritoneal carcinomatosis. Acta Pathol Microbiol Scand 1953; 33:10-21.
95. Bergman F. Carcinoma of the ovary: a clinical-pathological study of 86 autopsied cases with special reference to mode of spread. Acta Obstet Gynecol Scand 1966; 45:211.
96. Abrams LA, Spiro R, Goldstein N. Metastases in carcinoma. Cancer 1950; 3:74.
97. Burghardt E, Girardi F, Lahousen M, et al. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991; 40:103-106.
98. Pettersson F. Annual Report on the Results of Treatment in Gynecological Cancer. Stockholm: International Federation of Gynecology and Obstetrics, 1994.
99. Moore DH. Primary surgical management of early epithelial ovarian carcinoma. In: Rubin SC, Sutton GP, eds. Ovarian Cancer. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001:201-218.
100. Scully RE. Histological Typing of Ovarian Tumours (WHO. World Health Organization. International Histological Classification of Tumours). 2nd ed. Berlin: Springer-Verlag, 1999.
101. Robboy SJ, Duggan M, Kurman RJ. The female reproductive system. In: Rubin E, Farber J, eds. Pathology. 2nd ed. Philadelphia: LB Lippincott, 1988.
102. Eastwood J. Mesonephroid (clear cell) carcinoma of the ovary and endometrium: a comparative prospective clinico-pathological study and review of literature. Cancer 1978; 41:1911-1928.
103. Herbst AL. Neoplastic diseases of the ovary. In: Mishell DR Jr., Stenchever MA, Droegemueller W, et al., eds. Comprehensive Gynecology. 3rd ed. St. Louis: Mosgy-Year Book, Inc., 1997: 901-944.
104. Fine G, Clarke HD, Horn RC Jr. Mesonephroma of the ovary. A clinical, morphological, and histogenetic appraisal. Cancer 1973; 31:398-410.
105. Aure JC, Hoeg K, Kolstad P. Psammoma bodies in serous carcinoma of the ovary. A prognostic study. Am J Obstet Gynecol 1971; 109:113-118.
106. Gilks CB, Bell DA, Scully RE. Serous psammocarcinoma of the ovary and peritoneum. Int J Gynecol Pathol 1990; 9:110-121.
107. Ronnett BM, Kurman RJ, Shmookler BM, et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol 1997; 21:1144-1155.
108. Cuatrecasas M, Matias-Guiu X, Prat J. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Am J Surg Pathol 1996; 20:739-746.
109. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Hum Pathol 1996; 27:165-171.
110. Long ME, Taylor HCJ. Endometrioid carcinoma of the ovary. Am J Obstet Gynecol 1964; 90:936-950.
111. Schueller EF, Kirol PM. Prognosis in endometrioid carcinoma of the ovary. Obstet Gynecol 1966; 27:850-858.
112. Stern RC, Dash R, Bentley RC, et al. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 2001; 20:133-139.
113. Kline RC, Wharton JT, Atkinson EN, et al. Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol 1990; 39:337-346.
114. Czernobilsky B, Silverman BB, Mikuta JJ. Endometrioid carcinoma of the ovary. A clinicopathologic study of 75 cases. Cancer 1970; 26:1141-1152.
115. Tidy J, Mason WP. Endometrioid carcinoma of the ovary: a retrospective study. Br J Obstet Gynaecol 1988; 95:1165-1169.
116. Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol 1985; 16:28-34.
117. DiSilvestro PA, Gajewski WH, Ludwig ME, et al. Malignant mixed mesodermal tumors of the ovary. Obstet Gynecol 1995; 86:780-782.
118. Dehner LP, Norris HJ, Taylor HB. Carcinosarcomas and mixed mesodermal tumors of the ovary. Cancer 1971; 27:207-216.
119. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998; 70: 255-258.
120. Scully RE, Young RH, Clement PB. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament, Third Series, Fascicle 23. Washington, D.C.: Armed Forces Institute of Pathology, 1999.
121. Ohkawa K, Amasaki H, Terashima Y, et al. Clear cell carcinoma of the ovary: light and electron microscopic studies. Cancer 1977; 40:3019-3029.
122. Brescia RJ, Dubin N, Demopoulos RI. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. Int J Gynecol Pathol 1989; 8:132-138.
123. Hitti IF, Glasberg SS, Lubicz S. Clear cell carcinoma arising in extraovarian endometriosis: report of three cases and review of the literature. Gynecol Oncol 1990; 39:314-320.
124. Wheeler JE. Pathology of malignant ovarian epithelial tumors and miscellaneous and rare ovarian and paraovarian neoplasms. In: Rubin SC, Sutton GP, eds. Ovarian Cancer 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001:99-134.
125. Roth LM, Czernobilsky B. Ovarian Brenner tumors. II. Malignant. Cancer 1985; 56:592-601.
126. Austin RM, Norris HJ. Malignant Brenner tumor and transitional cell carcinoma of the ovary: a comparison. Int J Gynecol Pathol 1987; 6:29-39.
127. Lele SB, Piver MS, Barlow JJ, et al. Squamous cell carcinoma arising in ovarian endometriosis. Gynecol Oncol 1978; 6:290-293.
128. Pins MR, Young RH, Daly WJ, et al. Primary squamous cell carcinoma of the ovary. Report of 37 cases. Am J Surg Pathol 1996; 20:823-833.
129. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971; 37:1-9.
130. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971; 50:1-7.
131. Serov SF, Scully RE, Sobin LH. International Histological Classification and Staging of Tumors. No. 9 Histologic Typing of Ovarian Tumors. Geneva: World Health Organization, 1973.
132. Trimble CL, Trimble EL.Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1994; 55:S52-S61.
133. Nayar R, Siriaunkgul S, Robbins KM, et al. Microinvasion in low malignant potential tumors of the ovary. Hum Pathol 1996; 27: 521-527.
134. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol 1990; 21:397-403.
135. Chu CS, Randall TC, Mikuta JJ. Low Malignant Potential Tumors of the Ovary. Baltimore, MD: Post Graduate Obstetrics & Gynecology, Inc., 1998:1-6.
136. Norris HJ, Mount PM. Pathology of ovarian tumors of low malignant potential. In: Rutledge F, Wharton T, Gershenson D, eds. Gynecologic Cancer: Diagnosis and Treatment Strategies. Austin: University of Texas Press, 1987:171-192.
137. Harlow BL, Weiss NS, Lofton S. Epidemiology of borderline ovarian tumors. J Natl Cancer Inst 1987; 78:71-74.
138. Trimble EL, Trimble CL. Epithelial ovarian tumors of low malignant potential. In: Markman M, Hoskins WJ, eds. Cancer of the Ovary. New York: Raven Press, Ltd., 1993.
139. Harlow BL, Weiss NS, Roth GJ, et al. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 1988; 48:5849-5852.
140. Yazigi R, Sandstad J, Munoz AK. Primary staging in ovarian tumors of low malignant potential. Gynecol Oncol 1988; 31:402-408.
141. Sutton GP. Ovarian tumors of low malignant potential. In: Rubin SC, Sutton GP, eds. Ovarian Cancer. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001:399-417.
142. Buttini M, Nicklin JL, Crandon A. Low malignant potential ovarian tumours: a review of 175 consecutive cases. Aust N Z J Obstet Gynaecol 1997; 37:100-103.
143. Nakashima N, Nagasaka T, Oiwa N, et al. Ovarian epithelial tumors of borderline malignancy in Japan. Gynecol Oncol 1990; 38:90-98.
144. Chambers JT, Merino MJ, Kohorn EI, et al. Borderline ovarian tumors. Am J Obstet Gynecol 1988; 159:1088-1094.
145. Julian CG, Woodruff JD. The biologic behavior of low-grade papillary serous carcinoma of the ovary. Obstet Gynecol 1972; 40:860-867.
146. Nikrui N. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecol Oncol 1981; 12:107-119.
147. Nation JG, Krepart GV. Ovarian carcinoma of low malignant potential: staging and treatment. Am J Obstet Gynecol 1986; 154:290-293.
148. Kliman L, Rome RM, Fortune DW. Low malignant potential tumors of the ovary: a study of 76 cases. Obstet Gynecol 1986; 68:338-344.
149. Bostwick DG, Tazelaar HD, Ballon SC, et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986; 58:2052-2065.
150. Fort MG, Pierce VK, Saigo PE, et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989; 32:269-272.
151. Barnhill D, Heller P, Brzozowski P, et al. Epithelial ovarian carcinoma of low malignant potential. Obstet Gynecol 1985; 65:53-59.
152. Katzenstein AL, Mazur MT, Morgan TE, et al. Proliferative serous tumors of the ovary. Histologic features and prognosis. Am J Surg Pathol 1978; 2:339-355.
153. Barnhill DR, Kurman RJ, Brady MF, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13:2752-2756.
154. De Iaco P, Ferrero A, Rosati F, et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol 2009; 35:643-648.
155. Uzan C, Kane A, Rey A, et al. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol 2010; 21(1):55-60.
156. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996; 20:1319-1330.
157. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20:1331-1345.
158. Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 1999; 23:397-409.
159. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31:539-557.
160. Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary. Am J Obstet Gynecol 1959; 77:197.
161. Raju U, Fine G, Greenawald KA, et al. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases. Hum Pathol 1989; 20:426-436.
162. Truong LD, Maccato ML, Awalt H, et al. Serous surface carcinoma of the peritoneum: a clinicopathologic study of 22 cases. Hum Pathol 1990; 21:99-110.
163. Lele SB, Piver MS, Matharu J, et al. Peritoneal papillary carcinoma. Gynecol Oncol 1988; 31:315-320.
164. Chu CS, Menzin AW, Leonard DG, et al. Primary peritoneal carcinoma: a review of the literature. Obstet Gynecol Surv 1999; 54:323-335.
165. Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993; 50:347-351.
166. Fromm GL, Gershenson DM, Silva EG. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990; 75:89-95.
167. Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993; 51:171-174.
168. Dalrymple JC, Bannatyne P, Russell P, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989; 64:110-115.
169. Altaras MM, Aviram R, Cohen I, et al. Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. Gynecol Oncol 1991; 40:230-236.
170. Zhou J, Iwasa Y, Konishi I, et al. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Cancer 1995; 76:429-436.
171. Kannerstein M, Churg J, McCaughey WT, et al. Papillary tumors of the peritoneum in women: mesothelioma or papillary carcinoma. Am J Obstet Gynecol 1977; 127:306-314.
172. Ransom DT, Patel SR, Keeney GL, et al. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platinbased chemotherapy. Cancer 1990; 66:1091-1094.
173. August CZ, Murad TM, Newton M. Multiple focal extraovarian serous carcinoma. Int J Gynecol Pathol 1985; 4:11-23.
174. Eltabbakh GH, Piver MS, Natarajan N, et al. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol 1998; 91:254-259.
175. Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol 1996; 60:393-396.
176. Dvoretsky PM, Richards KA, Angel C, et al. Distribution of disease at autopsy in 100 women with ovarian cancer. Hum Pathol 1988; 19:57-63.
177. Gooneratne S, Sassone M, Blaustein A, et al. Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. Int J Gynecol Pathol 1982; 1:258-269.
178. White PF, Merino MJ, Barwick KW. Serous surface papillary carcinoma of the ovary: a clinical, pathologic, ultrastructural, and immunohistochemical study of 11 cases. Pathol Annu 1985; 20 (pt 1):403-418.
179. Kupryjanczyk J, Thor AD, Beauchamp R, et al. Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. Mod Pathol 1996; 9:166-173.
180. Pejovic T, Heim S, Mandahl N, et al. Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin. Int J Cancer 1991; 47:358-361.
181. Mok CH, Tsao SW, Knapp RC, et al. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 1992; 52:5119-5122.
182. Jacobs IJ, Kohler MF, Wiseman RW, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992; 84:1793-1798.
183. Li S, Han H, Resnik E, et al. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 1993; 51: 21-25.
184. Tsao SW, Mok CH, Knapp RC, et al. Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. Gynecol Oncol 1993; 48:5-10.
185. Muto MG, Welch WR, Mok SC, et al. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res 1995; 55:490-492.
186. Schorge JO, Muto MG, Welch WR, et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998; 90:841-845.
187. Bandera CA, Muto MG, Welch WR, et al. Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene 1998; 16:3455-3459.
188. Moll UM, Valea F, Chumas J. Role of p53 alteration in primary peritoneal carcinoma. Int J Gynecol Pathol 1997; 16:156-162.
189. Kurman RJ, Norris HJ. Malignant germ cell tumors of the ovary. Hum Pathol 1977; 8:551-564.
190. Schwartz PE, Morris JM. Serum lactic dehydrogenase: a tumor marker for dysgerminoma. Obstet Gynecol 1988; 72:511-515.
191. Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer 1976; 38: 2404-2419.
192. Nawa A, Obata N, Kikkawa F, et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol 2001; 184:1182-1188.
193. Kurman RJ, Norris HJ. Embryonal carcinoma of the ovary: a clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer 1976; 38:2420-2433.
194. Chapman DC, Grover R, Schwartz PE. Conservative management of an ovarian polyembryoma. Obstet Gynecol 1994; 83: 879-882.
195. Tsukahara Y, Fukuta T, Yamada T, et al. Retroperitoneal giant tumor formed by migrating polyembryoma with numerous embryoid bodies from an ovarian mixed germ cell tumor. Gynecol Obstet Invest 1991; 31:58-60.
196. Young RH, Scully RE. Ovarian sex cord-stromal tumours: recent advances and current status. Clin Obstet Gynaecol 1984; 11:93-134.
197. Schwartz PE, Smith JP. Treatment of ovarian stromal tumors. Am J Obstet Gynecol 1976; 125:402-411.
198. Ohel G, Kaneti H, Schenker JG. Granulosa cell tumors in Israel: a study of 172 cases. Gynecol Oncol 1983; 15:278-286.
199. Bennington JL, Ferguson BR, Haber SL. Incidence and relative frequency of benign and malignant ovarian neoplasms. Obstet Gynecol 1968; 32:627-632.
200. Fox H, Agrawal K, Langley FA. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 1975; 35:231-241.
201. Evans AT 3rd, Gaffey TA, Malkasian GD Jr., et al. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980; 55:231-238.
202. Nakashima N, Young RH, Scully RE. Androgenic granulosa cell tumors of the ovary. A clinicopathologic analysis of 17 cases and review of the literature. Arch Pathol Lab Med 1984; 108:786-791.
203. Bjorkholm E, Silfversward C. Prognostic factors in granulosa-cell tumors. Gynecol Oncol 1981; 11:261-274.
204. Malmstrom H, Hogberg T, Risberg B, et al. Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 1994; 52:50-55.
205. Piura B, Nemet D, Yanai-Inbar I, et al. Granulosa cell tumor of the ovary: a study of 18 cases. J Surg Oncol 1994; 55:71-77.
206. Schwartz PE, Price FV, Snyder MK. Management of ovarian stromal tumors. In: Rubin SC, Sutton GP, eds. Ovarian Cancer. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001:383-398.
207. Hines JF, Khalifa MA, Moore JL, et al. Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol 1996; 60:484-488.
208. Young RH, Dickersin GR, Scully RE. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol 1984; 8:575-596.
209. Roth LM, Nicholas TR, Ehrlich CE. Juvenile granulosa cell tumor: a clinicopathologic study of three cases with ultrastructural observations. Cancer 1979; 44:2194-2205.
210. Tamimi HK, Bolen JW. Enchondromatosis (Ollier’s disease) and ovarian juvenile granulosa cell tumor. Cancer 1984; 53:1605-1608.
211. Velasco-Oses A, Alonso-Alvaro A, Blanco-Pozo A, et al. Ollier’s disease associated with ovarian juvenile granulosa cell tumor. Cancer 1988; 62:222-225.
212. Lewis RJ, Ketcham AS. Maffucci’s syndrome: functional and neoplastic significance. Case report and review of the literature. J Bone Joint Surg Am 1973; 55:1465-1479.
213. Bjorkholm E, Silfversward C. Theca-cell tumors. Clinical features and prognosis. Acta Radiol Oncol 1980; 19:241-244.
214. Zhang J, Young RH, Arseneau J, et al. Ovarian stromal tumors containing lutein or Leydig cells (luteinized thecomas and stromal Leydig cell tumors)-a clinicopathological analysis of fifty cases. Int J Gynecol Pathol 1982; 1:270-285.
215. Samanth KK, Black WC III. Benign ovarian stromal tumors associated with free peritoneal fluid. Am J Obstet Gynecol 1970; 107:538-545.
216. Meigs JV, Cass JW. Fibroma of the ovary with ascites and hydrothorax with a report of seven cases. Am J Obstet Gynecol 1937; 107:538.
217. Prat J, Scully RE. Cellular fibromas and fibrosarcomas of the ovary: a comparative clinicopathologic analysis of seventeen cases. Cancer 1981; 47:2663-2670.
218. Chalvardjian A, Scully RE. Sclerosing stromal tumors of the ovary. Cancer 1973; 31:664-670.
219. Marelli G, Carinelli S, Mariani A, et al. Sclerosing stromal tumor of the ovary. Report of eight cases and review of the literature. Eur J Obstet Gynecol Reprod Biol 1998; 76:85-89.
220. Ho Yuen B, Robertson DI, Clement PB, et al. Sclerosing stromal tumor of the ovary. Obstet Gynecol 1982; 60:252-256.
221. Quinn MA, Oster AO, Fortune D, et al. Sclerosing stromal tumour of the ovary case report with endocrine studies. Br J Obstet Gynaecol 1981; 88:555-558.
222. Damajanov I, Drobnjak P, Grizelj V, et al. Sclerosing stromal tumor of the ovary: a hormonal and ultrastructural analysis. Obstet Gynecol 1975; 45:675-679.
223. Morris JM, Scully RE. Endocrine Pathology of the Ovary. St. Louis: Mosby, 1958.
224. Young RH, Scully RE. Ovarian Sertoli cell tumors: a report of 10 cases. Int J Gynecol Pathol 1984; 2:349-363.
225. Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9:543-569.
226. Zaloudek C, Norris HJ. Sertoli-Leydig tumors of the ovary. A clinicopathologic study of 64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol 1984; 8:405-418.
227. Hart WR, Kumar N, Crissman JD. Ovarian neoplasms resembling sex cord tumors with annular tubules. Cancer 1980; 45:2352-2363.
228. Tavassoli FA, Norris HJ. Sertoli tumors of the ovary. A clinicopathologic study of 28 cases with ultrastructural observations. Cancer 1980; 46:2281-2297.
229. Martin-Jimenez A, Condom-Munro E, Valls-Porcel M, et al. Gynandroblastoma of the ovary. Review of the literature. J Gynecol Obstet Biol Reprod (Paris) 1994; 23:391-394.
230. Novak ER. Gynandroblastoma of the ovary: review of 8 cases from the ovarian tumor registry. Obstet Gynecol 1967; 30:709-715.
231. Hayes MC, Scully RE. Stromal luteoma of the ovary: a clinicopathological analysis of 25 cases. Int J Gynecol Pathol 1987; 6: 313-321.
232. Roth LM, Sternberg WH. Ovarian stromal tumors containing Leydig cells. II. Pure Leydig cell tumor, non-hilar type. Cancer 1973; 32:952-960.
233. Hayes MC, Scully RE. Ovarian steroid cell tumors (not otherwise specified). A clinicopathological analysis of 63 cases. Am J Surg Pathol 1987; 11:835-845.
234. Scully RE. Gonadoblastoma: a gonadal tumor related to dysgerminoma (seminoma) and capable of sex hormone production. Cancer 1953; 6:455-463.
235. Scully RE. Gonadoblastoma. A review of 74 cases. Cancer 1970; 25:1340-1356.